Poster: CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
Year: 2022
Type: article
Authors: Catherine C. Coombs, John M. Pagel, Nirav N. Shah, Nicole Lamanna, Talha Munir, Ewa Lech-Maranda, Toby A. Eyre, Jennifer A. Woyach, William G. Wierda, Chan Y. Cheah, Jonathon B. Cohen, Lindsey E. Roeker, Manish R. Patel, Bita Fakhri, Minal A. Barve, Constantine S. Tam, David Lewis, James N. Gerson, Alvaro Alencar, Chaitra Ujjani, Ian Flinn, Suchitra Sundaram, Shuo Ma, Deepa Jagadeesh, Joanna Rhodes, Justin Taylor, Omar Abdel-Wahab, Paolo Ghia, Stephen J. Schuster, Denise Wang, Binoj Nair, Edward Zhu, Donald E. Tsai, Matthew S. Davids, Jennifer R. Brown, Wojciech Jurczak, Anthony R. Mato
Institutions: University of North Carolina at Chapel Hill, Loxo Oncology at Lilly (United States), Medical College of Wisconsin, Herbert Irving Comprehensive Cancer Center, Columbia University, St James's University Hospital, Instytut Hematologii i Transfuzjologi, Churchill Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The University of Texas MD Anderson Cancer Center, Sir Charles Gairdner Hospital, Linear Clinical Research, Emory University, Winship Cancer Institute, Memorial Sloan Kettering Cancer Center, University of California, San Francisco, Mary Crowley Cancer Research Center, The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, Derriford Hospital, Abramson Cancer Center, University of Pennsylvania, University of Miami, Fred Hutch Cancer Center, Sarah Cannon, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Cleveland Clinic, Northwell Health, Hofstra University, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Harvard University, Dana-Farber Cancer Institute, The Maria Sklodowska-Curie National Research Institute of Oncology
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4296612934